...KRAS, CDKN2A, TP53, and SMAD4-are central to the pathogenesis of pancreatic ductal adenocarcinoma (PDAC) and critically ...
...KRAS-G12C inhibitors, as well as ADCs and BsAbs, highlighting both shared and distinct patterns of cardiotoxicity. As ta...
...KRAS and KRAS-SOS1 complexes as a case study, demonstrating its ability to identify known functional and allosteric site...
...KRAS, TP53) mutations. The most common treatment-emergent adverse events were diarrhea, nausea, and constipation. N+T in...
...KRAS in-frame duplication. This pediatric case shows that T-MCA can form postnatally after focal M1 injury and may be mi...
...KRAS gene driver mutations, which promote tumor proliferation, invasion, and immunosuppression of the tumor microenviron...
...KRAS), cancer cells can adapt to stress-induced conditions. One of the adaptations that is commonly observed in non-smal...
...Kras-induced lung tumour development and reveal a novel, p53-independent requirement for Huwe1 in LUAD. Mechanistically,...
...KRAS, for the treatment of KRAS/TP53 co-mutant tumors. AUTACE targets tumors via TP53-specific TCRs, elicits antitumor C...
...KRAS mutation, and microsatellite stability status (MSS). CAF DOG1 expression was identified in MSS conventional adenoca...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
